Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CTSA | P10619 | 14/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458252 | 0.85 | CTSA (0.36) | ALDH1A1CTSA | |
| SCHEMBL5455885 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CTSA | |
| SCHEMBL5449339 | 0.77 | CTSA (0.33) | ALDH1A1CTSATSHRNOS1HSD17B10 | |
| SCHEMBL31079263 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CTSAHSD17B10 | |
| SCHEMBL5585939 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CTSATSHRNOS1HSD17B10 | |
| SCHEMBL7470027 | 0.74 | NPC1 (0.42) | ALDH1A1CTSAHSD17B10 | |
| SCHEMBL27532419 | 0.73 | MAPKAPK2 (0.35) | ALDH1A1CTSATSHRNOS1HSD17B10 | |
| SCHEMBL28275811 | 0.73 | ALDH1A1 (0.33) | ALDH1A1CTSATSHRNOS1HSD17B10 | |
| SCHEMBL10591999 | 0.72 | ALDH1A1 (0.39) | ALDH1A1CTSATSHRNOS1HSD17B10 | |
| SCHEMBL7686450 | 0.72 | ALDH1A1 (0.39) | ALDH1A1CTSATSHRNOS1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | ALDH1A1 743/4885CTSA 1278/4885TSHR 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.